Kornimate/medical-research-clean huggingface dataset:
cognitive behavioural therapy software for the treatment of depression in people with multiple sclerosis

Conditions: Depression; Multiple Sclerosis

Summary: guidance issued by the united kingdom (uk) national institute for health and clinical excellence (nice) recommends the use of computerised cognitive behavioural therapy (ccbt) 'beating the blues' (btb) in treatment of depression. however ccbt has not been designed specifically for use by people with multiple sclerosis (ms) and may not be effective or appropriate for use by people with physical disabilities or cognitive symptoms. there would therefore be value in conducting a trial of the effectiveness of ccbt for depression in people with ms. the aim of this pilot study is to test the feasibility of a randomised control trial (rct) of ccbt for depression in people with ms. the objective is to undertake a pilot rct of comparison of ccbt with usual care including 3 month follow up to identify a realistic patient recruitment rate and provide reliable estimates of other parameters needed for designing a definitive rct including the sample size. other outcomes to be measured include estimates of the effect on depression and quality of life. participants will be assessed as experiencing clinical levels of depression and be recruited from two participating ms centres. the outcomes of the study will be (1) preliminary indication of the impact of ccbt on depression in ms; and, (2) a well researched protocol for a definitive rct of the effectiveness of ccbt in treating depression in people with ms.


Eligibility criteria:
inclusion criteria: * aged 18+ * diagnosis of ms confirmed by neurologist * beck depression inventory-ii score of at least 14 on two consecutive occasions * not currently or within past three months receiving any treatment from a psychologist, psychotherapist or psychiatrist. * willingness to be randomised to ccbt, at home or primary care facility or treatment as usual. exclusion criteria: * unable to read or write english * beck depression inventory score of at least 29 on two consecutive occasions * active suicidal ideas * current or life-time diagnosis of any of the following: * psychosis * organic mental disorder; * alcohol or drug dependency * kurtzke expanded disability status scale (edss) score of 8.5 or above * unable to use the ccbt package due to physical disability * unable to use the ccbt package due to cognitive symptoms (mini-mental state of 20 below or if, in the opinion of the study psychologist, the individual would be unlikely to benefit from ccbt)

Keywords: cbt-software computerised cognitive behavioural therapy ccbt cognitive therapy therapy, computer-assisted depression multiple sclerosis
glycemic and insulinemic responses of low-carbohydrate snack foods

Conditions: Healthy

Summary: the aim of this study is develop recipes containing cho less than icr, prepare new snacks alternatives that could be consumed without need for additional insulin doses, and evaluate the glycemic and insulinemic responses of these recipes. a randomized crossover trial will include 15 healthy adults aged 19-30 years. all participants will consume 3 test foods and reference food (glucose solution, 2 times) in a random order. blood samples will be collected at time points 0,15, 30, 45, 60, 90 and 120 min. glucose and insulin analyzes will be performed from blood samples. the results of these time points will be marked on the chart and the incremental area under the curve (iauc) will be calculated for both glucose and insulin.


Eligibility criteria:
inclusion criteria: * healthy volunteer * normal body weight (18.5-25 kg / m2 bmi) * 19-30 years old exclusion criteria: * use of tobacco, * weight change of \>5 kg in the last 3 months * the presence of any chronic disease or lactose intolerance, * regular medicine use, * pregnancy or lactation, * performing competitive sports or endurance sports, * fasting plasma glucose concentration \>100 mg / dl, * the presence of eating disorder, * sensitivity or allergies to any food that used in the study

Keywords: glycemic index insulinemic index low carbohydrate snack type 1 diabetes
an fmri study of the effect of intravenous oxytocin vs. placebo on response inhibition and face processing in autism

Conditions: Autism

Summary: to study the effect of oxytocin on face processing and response inhibition in autistic adults by fmri.

autism is a developmental disorder affecting approximately 60/10,000 individuals. it is characterized by social and language deficits and repetitive behaviors/restricted interests. functional imaging is becoming a very useful tool in trying to understand the neurobiology of autism. oxytocin is a hormone produced by the brain to assist with labor and lactation. recent evidence suggests that it may be involved in social attachment and in repetitive behaviors. in this project, we will study how oxytocin changes the way the brain of autistic adults processes faces, and deals with response inhibition (the ability to interrupt ongoing responses should they prove ineffective or interfering with attaining a goal). there is currently no functional imaging data assessing the effect of oxytocin on the brain. we will explore the activation patterns in response to oxytocin across circuits involved in social cognition (face fusiform area) and response inhibition (caudate, orbitofrontal and dorsolateral cortex) by administering a specific fmri task activating those circuits before and during an oxytocin infusion. we will also explore the effect of oxytocin in these areas by administering specific cognitive testing not associated with fmri before and during oxytocin infusion.

Eligibility criteria:
inclusion criteria: 1. meet dsm-iv, adi, or ados criteria for autism spectrum disorder. 2. age 18-50. 3. be seen as outpatients 4. iq\>80 5. 5. demonstrate capacity to provide authorized informed consent or provide consent for participation by an approved surrogate on the autistic individual's behalf exclusion criteria: 1. subjects who are pregnant or nursing mothers. sexually active women of childbearing potential who are not using adequate birth control measures. 2. subjects with epilepsy. 3. subjects with a history of schizophrenia, schizoaffective disorder or other axis 1 mental disorders, such as bipolar disorder. 4. subjects reporting history of encephalitis, phenylketonuria, tuberous sclerosis, fragile x syndrome, anoxia during birth, neurofibromatosis, hypomelanosis, hypothyroidism, duchenne muscular dystrophy, and maternal rubella 5. subjects who have received depot neuroleptic medication, or other psychoactive drugs within the past 5 weeks. 6. subjects with renal or liver disease or abnormalities in blood chemistry. 7. any metallic prosthesis such as plates, pins and screws, shrapnel, metallic foreign body, vascular or neurosurgical clips that may be incompatible with the mri and any electrical devices such as a pacemaker or a defibrillator 8. claustrophobia
clinical evaluation of primary sampling scatter correction for chest tomosynthesis

Conditions: Pulmonary Nodule, Solitary; Pulmonary Nodule, Multiple

Summary: this is a study that will evaluate the utility of a scatter reduction technique in reducing dose and increasing the sensitivity of stationary digital chest tomosynthesis (s-dct) in the detection of lung lesions.

digital tomosynthesis is an imaging modality that produces 3d sectional information using x-ray projections acquired over a limited scanning angle. scatter is known to be the primary source of image degradation in x-ray based imaging. the investigators have developed an approach that measures scatter through a low dose (3% of the conventional scan) scatter measurement technique. preliminary studies have shown that scatter reduction in dct can significantly improve quality. the approach will characterize the reader confidence in lung nodule detection in a scatter corrected chest tomosynthesis imaging approach as compared to the conventional chest tomosynthesis. fifty (50) patients who have undergone a clinical non-contrast ct with lung nodules will be asked to have an s-dct (scan) within 4 weeks (+/- 2 week) of their clinical ct with no intervening procedures or therapies (i.e. biopsy of lung nodules). investigators will then perform a reader study to evaluate the radiologist reader confidence in images generated from the scatter reduction technique versus more conventional chest tomosynthesis imaging.

Eligibility criteria:
inclusion criteria: * patients with known lung lesion(s) * patients having undergone a chest ct * patients 18 years of age and older * patients able to provide informed consent exclusion criteria: * patients who may not fit on a 35 x 35 detector (bmi \> 35) * planned procedures or therapies during study (in between soc scans and study scan on s-dct) (biopsy or removal of lung lesion) * any woman who is pregnant, has reason to believe she is pregnant, or is lactating

Keywords: chest lung tomography scatter
intraoperative cone-beam ct for percutaneous nephrolithotomy

Conditions: Nephrolithiasis

Summary: percutaneous nephrolithotomy (pcnl) is a first-line treatment for kidney stones \>2cm. frequently, patients require multiple procedures to address their stone burden. the decision to proceed with a second-look procedure is based on follow-up ct imaging, which is obtained postoperatively. in this study, we propose the use of a portable ct scan technology to obtain follow-up imaging while the patient is still under anesthesia for the initial procedure. the goal of this study is to determine whether this allows the surgeon to identify residual fragments and render the patient stone-free within a single anesthetic event.

percutaneous nephrolithotomy (pcnl) is considered a first-line management option for kidney stones larger than two centimeters. unfortunately, because of the large stone burden, up to 70% of these patients are left with residual stone fragments after their initial pcnl. additionally, an estimated 20% to 60% of such patients ultimately require further interventions due to residual stone fragments. the need for a subsequent procedure is determined by postoperative abdominal computed tomography (ct) imaging, which is routinely performed on the first postoperative day at this institution. the decision to proceed with a second procedure is based on findings from this postoperative ct scan. cone-beam ct (cbct) is a novel portable imaging technique that can allow cross-sectional imaging to be obtained intraoperatively, rather than post-operatively. incorporating this modality would allow the surgeon to determine whether the procedure should be continued, in the event of residual fragments, or if it can be safely concluded. this would obviate the need for dedicated postoperative ct scans and, more importantly, reduce the need for subsequent procedures and consequently decrease the patient's length of stay.

Eligibility criteria:
inclusion criteria: 1. patients \>18 years old 2. scheduled for percutaneous nephrolithotomy with stone fragmentation (laser/ultrasonic/mechanical) 3. for the prospective intervention arm, willingness to consent to participate in the study exclusion criteria: 1. patients whose habitus does not allow for the use of the cone beam ct machine 2. patients whose stones only reside within the mid or distal ureter(s) and thus would not be easily imaged with cone beam ct 3. patients who have had lithotripsy on their renal unit within the prior 90 days 4. pregnant patients

Keywords: percutaneous nephrolithotomy cone beam ct
tdcs in tourette (tic-tdcs)

Conditions: Tourette Syndrome

Summary: double-blind randomized, sham-controlled clinical trial of 1 ma bilateral supplementary motor area in adolescents/adults with tourette syndrome (ts). the primary objectives are to assess and quantify the safety and efficacy on tic severity of 5 inhibitory sessions of active vs. sham tdcs sessions during active tic suppression, and to explore the differences in brain functional activity before and after 5 sessions of active or sham cathodal tdcs in adolescents and adults with ts. secondary objectives include the assessment of the severity of comorbidities after 5 inhibitory tdcs sessions.


Eligibility criteria:
inclusion criteria: * participants who meet diagnostic and statistical manual of mental disorders criteria for ts (apa, dsm v). * 16 years of age or older. * a "moderately ill" or worse score on the clinical global impression severity scale (cgi-s). * a total motor tic or vocal tic severity score greater or equal to 15/25 on the yale global tic severity scale (ygtss) or a combined score greater than 22/50. * participants should be either un-medicated or on stable medication treatment for tics for the previous 3 months. if receiving botulinum toxin treatment, their enrolment should be at least 16 weeks after the last treatment session. * psychiatric comorbidities should be clinically stable; treatment has not changed in the last 3 months. exclusion criteria: participants will be excluded from the study if they meet any of the following criteria: * have a metal object/implant in their brain, skull, scalp, or neck. * have an implantable device (e.g., cardiac pacemaker). * have a diagnosis of epilepsy or cardiac disease. * have a history of traumatic brain injury, learning disability or dyslexia. * have a severe impediment in vision or hearing.
smoking cessation using motivational therapy and varenicline

Conditions: Smoking; HIV Infections

Summary: people that are infected with hiv appear to be especially susceptible to the adverse effects of cigarette smoking. the purpose of this study is to determine if quitting smoking by using a specialized smoking cessation treatment can prevent one from developing accelerated lung damage, particularly emphysema.

hiv-infected smokers are at increased risk for life-threatening diseases, such as pneumonia. to date, very little is known about the tobacco consumption characteristics of this at-risk population of smokers, but it has been well documented that they are at high risk for smoking-related co-morbidities. in addition, few effective cessation strategies have been described in hiv-infected populations. a specialized smoking cessation that combines recommendations from an existing scientifically-valid clinical guideline with motivational interviewing a new pharmacotherapeutic agent, may be an effective mechanism to apply to this vulnerable population of smokers. this initial, efficacy investigation has the potential to guide future treatment and research pertaining to tobacco cessation, respiratory illness and hiv.

Eligibility criteria:
inclusion criteria: 1. 18 years of age and older; 2. diagnosis of hiv; 3. self-reported smoking on a daily basis; 4. provide informed written consent exclusion criteria: 1. persons with active psychosis or impaired mental status as judged by the clinic staff and confirmed with a mini-mental status exam) 2. unable to understand spoken english 3. age less than 18 years. 4. pregnant women

Keywords: hiv positive smokers varenicline
radiochemotherapy followed by adjuvant chemotherapy based on gemcitabine in uterine cervical cancer

Conditions: Uterine Cervical Cancer

Summary: the scope of the trial is to assess the efficacy of the association gemcitabine-cisplatin + radiotherapy followed by an adjuvant chemotherapy


Eligibility criteria:
inclusion criteria: * age between 18 and 70 years old * cervical uterine cancer (epidermoid or adenocarcinoma, stage:from ib\> or = 4 cm to iv, according to figo classification) histologically proven * measurable lesions,clinically and by mri assessed * ps-who \ 70 per cent * life expectancy \> 3 months * hematologic function: leukocytes \ or = 1.5 g/l, platelets \> or = 100 g/l, hemoglobin \> or = 10 g/dl * hepatic function: asat and alat \< 2.5 uln * renal function: creatininemia \ 60 ml/min * no prior chemotherapy or radiotherapy * contraception * written informed consent signed exclusion criteria: * stage ib \< 4 cm or ivb * other histology than epidermoid or adenocarcinoma * distant metastases, including sus-clavicular adenopathy * contraindication to mri * pregnant or lactating woman * auto-immune disease * peripheric neuropathy, autograft or homograft, psychiatric disease * prior cancer (except cutaneous basocellular carcinoma and uterine cervical carcinoma in situ) * active infection * other clinical trial with an experimental drug * known positive serology (hiv, hbc, hbs)

Keywords: uterine cervical cancer
food-effect study in healthy participants

Conditions: Healthy

Summary: this study will evaluate the effect of food on the pharmacokinetics (pk) of a single dose of lasmiditan in healthy participants.

an open-label, cross-over, two-period, randomized, sequential study in order to investigate the effect of food on the pharmacokinetics of lasmiditan 200 mg. two single doses of lasmiditan will be administered with the participants in fed and fasted states.

Eligibility criteria:
inclusion criteria: * male or female aged 18-50 years. * able and willing to give written informed consent. * females of child bearing potential must be using or willing to use a medically acceptable method (as defined by the investigator) of birth control. * body mass index (bmi) within 19 and 29.9 kilograms per meter squared (kg/m²). * no clinically significant abnormalities (as determined by the principal investigator) in hematology, blood chemistry and urinalysis lab tests at screening. * no history of alcohol or drug abuse within the past year. negative urinary drugs of abuse and alcohol screen determined within 21 days of the start of the study and at check-in day -1. * must be able to understand the requirements of the study and must be willing to comply with the requirements of the study. exclusion criteria: * any medical condition or clinical laboratory test which in the judgment of the investigator makes the participant unsuitable for the study. * pregnant or breast-feeding women. * use of any prescription within 14 days prior to dosing (except hormonal contraceptives) or over the-counter medications, including vitamins and herbal or dietary supplements within 7 days prior to dosing unless approved by the investigator and medical monitor. * history within the previous 3 years or current evidence of abuse of any drug, prescription or illicit, or alcohol; a positive urine screen for drugs of abuse or alcohol. * history of orthostatic hypotension with or without syncope. * at imminent risk of suicide (positive response to question 4 or 5 on the columbia-suicide severity rating scale \[c-ssrs\]) or had a suicide attempt within 6 months prior to screening. * participation in any clinical trial of an experimental drug or device in the previous 30 days. * positive hepatitis c antibody, hepatitis b surface antigen, or positive human immunodeficiency virus (hiv) antibody. * donated plasma in the 7 days or blood in the 3 months preceding study drug administration. * inability to communicate well with the investigator and study staff (i.e., language problem, poor mental development or impaired cerebral function). * inability to fast or consume the food provided in the study. * relatives of, or staff directly reporting to, the investigator.
gemcitabine/capecitabine/zd6474 in advanced solid tumors

Conditions: Malignant Solid Tumour; Biliary Cancer; Pancreatic Cancer

Summary: zactima will be used in this study to determine the highest dose that can be given safely as well as the side effects of zactima when in combination with two fda approved drugs; gemcitabine and capecitabine. this combination will be given to patients with advanced solid tumors. once the highest dose of the combination has been determined, additional patients with biliary cancers (cholangiocarcinomas and gallbladder cancer) and locally advanced or metastatic pancreatic cancer will be treated at the highest determined dose for further studies.

this phase i study will access a novel regimen using a multi-targeted anti-angiogenic agent which targets the tyrosine kinase of vascular endothelial growth factor (vegf) receptor 2 and epidermal growth factor receptor (egfr) in combination with cytotoxic agents: gemcitabine and capecitabine. the rationale is based on observations that there is an additive / synergistic effect when cytotoxic agents are combined with angiogenesis inhibitors. there is also evidence that egfr mediated signaling pathways are potent stimulators of vegf production. also the concept of dual targeting of tumor and endothelial cells may provide more encouraging results.

Eligibility criteria:
inclusion criteria: * age 18 years or older * eastern cooperative oncology group (ecog) performance status of 0-1 (measure of your ability to perform everyday tasks) * life expectancy of at least three months blood samples and other testing may apply for further testing of eligibility. exclusion criteria: * uncontrolled illness (for example, current infections or heart conditions) * abnormal laboratory tests (such as blood or urine testing) * pregnant or breastfeeding women further exclusion criteria may apply.

Keywords: advanced solid tumors biliary or pancreatic malignancies
assessment of the impact of polycystic ovary syndrome on women's sexuality

Conditions: Polycystic Ovarian Syndrome (PCOS)

Summary: this study, titled sexopk, aims to evaluate the impact of polycystic ovary syndrome (pcos) on women's sexual health. pcos is a common endocrine disorder affecting 5-20% of women of reproductive age, often leading to hormonal imbalances, metabolic issues, and psychological distress. despite existing studies on the subject, the level of sexual distress associated with pcos-related sexual dysfunction remains unclear. the study will compare sexual function and distress levels between women diagnosed with pcos and a control group without pcos. participants will complete an online questionnaire assessing various aspects of sexual health, body image, anxiety, and depression. the findings may help healthcare professionals better understand and address sexual dysfunction in women with pcos.


Eligibility criteria:
inclusion criteria: for patients in the test group (pcos): * adults * carriers of medically diagnosed polycystic ovarian syndrome * non-opposition for patients in the control group: * adults * not carriers of polycystic ovarian syndrome * unopposed exclusion criteria: * patient under court protection, guardianship, or curatorship * does not understand or speak french

Keywords: polycystic ovary syndrome female sexuality quality of life sexual health